Skip to content
Screener

AnaptysBio, Inc. ANAB EV / EBITDA

EV / EBITDA at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
10.1×-0.2×
Eli Lilly logo
Eli LillyLLY
31.3×-7.9×
Pfizer logo
PfizerPFE
12.9×—
Amgen logo
AmgenAMGN
15.7×+0.7×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
15×+1.9×
Biogen logo
BiogenBIIB
17.9×+9.8×

Other financials

Income statement

See full
Revenue$25.6M-8.0%
Operating income-$34.6M-25.8%
Net income-$52.9M-34.5%
EPS (diluted)-$1.84-43.8%

Balance sheet

See full
Cash & equivalents$248.5M+152%
Total debt$13.6K-99.9%
Total equity$12.7M-62.5%
Total assets$329.7M-21.9%

Cash flow

See full
Operating cash flow-$25.9M-142%
CapEx$17.0K-51.4%
Free cash flow-$25.9M-142%

Valuation

See full
Market cap$1.62B+145%
Enterprise value$1.37B+117%
P/S7×+1.6×

Profitability

See full
Operating margin17.6%+9.6pp
Net margin-49.9%-22.6pp
FCF margin1.9%+1.0pp

Returns & leverage

See full
Return on equity-343.8%-1,012pp
Debt / equity0×-0.5×
Current ratio7.6×-0.7×

Where this comes from

Calculated from AnaptysBio, Inc.’s reported figures.

enterprise value/ebitda=32.6×

Based on the most recent quarter.

The source filing: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026. Open the filing →

Filed
May 12, 2026, 4:20 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-219515

FAQ

What is AnaptysBio, Inc.'s EV / EBITDA?
AnaptysBio, Inc. (ANAB) reported EV / EBITDA of 32.6× in Q1 2026.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.

Ask your AI about AnaptysBio, Inc.'s ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude